Henry Schein, Inc. (NASDAQ:HSIC) Receives $76.42 Average PT from Analysts

Henry Schein, Inc. (NASDAQ:HSIC) has been assigned an average recommendation of “Hold” from the twelve brokerages that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, six have issued a hold recommendation and five have issued a buy recommendation on the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $76.4167.

A number of analysts recently commented on HSIC shares. Barrington Research set a $79.00 target price on shares of Henry Schein and gave the stock an “outperform” rating in a research note on Wednesday, November 5th. Wall Street Zen raised shares of Henry Schein from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. Morgan Stanley lifted their price objective on shares of Henry Schein from $55.00 to $58.00 and gave the stock an “underweight” rating in a research note on Wednesday, November 5th. Wells Fargo & Company upped their target price on Henry Schein from $70.00 to $76.00 and gave the company an “equal weight” rating in a research report on Wednesday, November 5th. Finally, Mizuho set a $81.00 target price on Henry Schein and gave the stock a “neutral” rating in a research note on Tuesday, January 20th.

Institutional Investors Weigh In On Henry Schein

A number of institutional investors and hedge funds have recently modified their holdings of the company. MAI Capital Management grew its holdings in Henry Schein by 7.5% in the third quarter. MAI Capital Management now owns 2,061 shares of the company’s stock valued at $137,000 after purchasing an additional 144 shares during the last quarter. Vanguard Personalized Indexing Management LLC boosted its position in shares of Henry Schein by 3.5% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 4,669 shares of the company’s stock worth $341,000 after buying an additional 157 shares in the last quarter. CW Advisors LLC boosted its position in shares of Henry Schein by 2.8% in the 2nd quarter. CW Advisors LLC now owns 5,913 shares of the company’s stock worth $432,000 after buying an additional 163 shares in the last quarter. TD Asset Management Inc grew its stake in Henry Schein by 0.8% in the 2nd quarter. TD Asset Management Inc now owns 22,016 shares of the company’s stock valued at $1,608,000 after acquiring an additional 164 shares during the last quarter. Finally, Truist Financial Corp increased its holdings in Henry Schein by 3.3% during the 3rd quarter. Truist Financial Corp now owns 5,540 shares of the company’s stock valued at $368,000 after acquiring an additional 175 shares in the last quarter. Institutional investors and hedge funds own 96.62% of the company’s stock.

Henry Schein Stock Down 1.3%

Shares of HSIC stock opened at $77.21 on Friday. The stock’s fifty day moving average price is $77.25 and its 200 day moving average price is $71.44. The company has a debt-to-equity ratio of 0.54, a current ratio of 1.40 and a quick ratio of 0.79. Henry Schein has a 1-year low of $60.56 and a 1-year high of $82.80. The company has a market cap of $9.09 billion, a price-to-earnings ratio of 24.43, a price-to-earnings-growth ratio of 2.33 and a beta of 0.88.

Henry Schein Company Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.